Skip to main content

Qelbree Disease Interactions

There are 4 disease interactions with Qelbree (viloxazine).

Moderate

Antidepressants (applies to Qelbree) mania

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bipolar Disorder

All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder. Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.

References

  1. Carpenter LL, Frank E, Kupfer DJ "Possible role of antidepressants in precipitating mania and hypomania in recurrent depression." Am J Psychiatry 145 (1988): 804-8
  2. Fox I, Clary C, Rickels K, Weise C, Schweizer E "Placebo-controlled trial of venlafaxine for the treatment of major depression." J Clin Psychopharmacol 11 (1991): 233-6
  3. Fabre LF, Rudolph R, Khan A "Venlafaxine in depressed outpatients." Psychopharmacol Bull 27 (1991): 141-4
  4. "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories (2001):
  5. Bick PA, Warren M "Two case reports of trazodone-induced mania." Am J Psychiatry 141 (1984): 1103-4
  6. Theilman SB, Christenbury MM "Hypomania following withdrawal of trazodone." Am J Psychiatry 143 (1986): 1482-3
  7. Lennhoff M "Trazodone-induced mania." J Clin Psychiatry 48 (1987): 423-4
  8. Jabeen S, Fisher CJ "Trazodone-induced transient hypomanic symptoms and their management." Br J Psychiatry 158 (1991): 275-8
  9. Zmitek A "Trazodone-induced mania." Br J Psychiatry 151 (1987): 274-5
  10. Itzchaky S, Emanuel D, Knobler HY, Maizel S, Mester R "Trazodone-induced mania." Br J Psychiatry 149 (1986): 787-9
  11. "Product Information. Desyrel (trazodone)." Bristol-Myers Squibb (2001):
  12. Fontaine R "Novel serotonergic mechanisms and clinical experience with nefazodone." Clin Neuropharmacol 16 Suppl 3 (1993): s45-50
  13. "Product Information. Serzone (nefazodone)." Bristol-Myers Squibb (2001):
  14. Aljeshi A, Jeffries JJ "Nefazodone-induced mania." Can J Psychiatry 40 (1995): 218
  15. "Product Information. Remeron (mirtazapine)." Organon (2001):
  16. Montgomery SA "Safety of mirtazapine: a review." Int Clin Psychopharmacol 10(suppl 4 (1995): 37-45
  17. Dubin H, Giannandrea P, Spier S "Nefazodone-induced mania." Am J Psychiatry 154 (1997): 578-9
  18. "Product Information. Qelbree (viloxazine)." Supernus Pharmaceuticals Inc (2021):
View all 18 references
Moderate

Viloxazine (applies to Qelbree) depression

Moderate Potential Hazard, Moderate plausibility.

Patients being treated with viloxazine should be monitored for clinical worsening and emergence of suicidal thoughts and behaviors. In clinical trials, higher rates of suicidal thoughts and behavior were reported in pediatric patients with attention deficit hyperactivity disorder (ADHD) receiving this drug than placebo. Prior to initiating treatment, patients should be screened for a personal or family history of suicide, bipolar disorder, and depression.

References

  1. "Product Information. Qelbree (viloxazine)." Supernus Pharmaceuticals Inc (2021):
Moderate

Viloxazine (applies to Qelbree) liver impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The effect of hepatic impairment on the pharmacokinetics of viloxazine is unknown. Viloxazine is not recommended in patients with hepatic impairment.

References

  1. "Product Information. Qelbree (viloxazine)." Supernus Pharmaceuticals Inc (2021):
Moderate

Viloxazine (applies to Qelbree) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

The exposure of viloxazine increases in patients with renal impairment. Dose reduction is recommended in patients with severe renal impairment (estimated glomerular filtration rate less than 30 mL/min/1.73 m3).

References

  1. "Product Information. Qelbree (viloxazine)." Supernus Pharmaceuticals Inc (2021):

Qelbree drug interactions

There are 256 drug interactions with Qelbree (viloxazine).

Qelbree alcohol/food interactions

There is 1 alcohol/food interaction with Qelbree (viloxazine).

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.